Compare GSK plc (GSK) vs Direxion Daily TSLA Bull 2X Shares (TSLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Direxion Daily TSLA Bull 2X Shares — how do they compare? GSK plc trades at $52.39 (market cap $101.34B), while Direxion Daily TSLA Bull 2X Shares trades at $12.18. The key difference: GSK plc pays a 3.49% dividend while Direxion Daily TSLA Bull 2X Shares pays none, and GSK plc is trading nearer its 52-week high, Direxion Daily TSLA Bull 2X Shares nearer its low. Which is the better fit depends on your goals.
| GSK | TSLL | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $61.18 | $23.03 |
52-Week Low | $36.20 | $10.29 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
TSLL is trading at $11.74, down 4.94% with bearish technical signals showing 15 sell indicators versus 4 buys. The stock faces resistance at $13 and finds support at $11. Recent news highlights continued investor interest in leveraged ETF strategies, with coverage focusing on derivative-based investment approaches. Financial ratios remain unavailable in current data.
The bearish technical outlook and lack of fundamental data create uncertainty. Investment opportunity depends on risk tolerance for leveraged ETF products, while risks include market volatility and dependency on underlying asset performance. Further fundamental analysis is needed for comprehensive assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Direxion Daily TSLA Bull 2X Shares
TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →
